La presencia de células en anillo de sello en la biopsia endoscópica no es un buen predictor para el diagnóstico de carcinoma gástrico de células en anillo de sello

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Resumen Introducción El carcinoma gástrico de células en anillo de sello (CGCAS) es un tipo histopatológico, que tiene menor respuesta a la quimioterapia (QT) y un peor pronóstico en los pacientes con cáncer gástrico (CG) avanzado. Se desconoce los valores diagnósticos de la presencia de células en anillo de sello (CAS) en la biopsia endoscópica, para el diagnóstico de CGCAS. Objetivo Determinar los valores diagnósticos de la presencia de CAS en la biopsia endoscópica para el diagnóstico de CGCAS en la biopsia de la pieza operatoria. Material y Método Estudio retrospectivo de pruebas diagnósticas. Se incluyeron los pacientes con CG operados en forma consecutiva entre 1996-2016. Se calculó los valores diagnósticos de la presencia de CAS en la biopsia endoscópica para el diagnóstico de CGCAS en la biopsia definitiva. Se utilizaron intervalos de confianza (IC) del 95%. Resultados Se incluyeron 851 pacientes. Un 16,3% tuvieron CAS en la biopsia endoscópica y la prevalencia de CGCAS fue de 16,4%. Los valores diagnósticos de la presencia de CAS de la biopsia endoscópica para el diagnóstico de CGCAS fueron: Valor predictivo positivo (VPP) de 56,1% (IC 95%, 47,8-64,1%); Valor predictivo negativo (VPN) de 91,3% (IC 95%, 89-93,1%); sensibilidad de 55,7% (IC 95%, 47,4-63,7%); especificidad de 91,4% (IC 95%, 89,1%-93,3%); Likelihood ratio (LR) positivo de 6,5 (IC 95%, 4,9-8,6); LR negativo de 0,48 (IC 95%, 0,4-0,6); probabilidad post-test positivo fue de 56,1% (IC 95%, 47,8-64,1%) y probabilidad post-test negativo fue de 8,7% (IC 95%, 6,9-11%). Conclusiones La presencia de CAS en la biopsia endoscópica es insuficiente para el diagnóstico de un CGCAS. La ausencia de CAS en la biopsia endoscópica tiene un alto valor predictivo negativo.

Translated abstract

Introduction Signet-ring cell carcinoma (SRCC) of the stomach is a histopathological type that has less response to chemotherapy and worse prognosis in patients with advanced gastric cancer, than other types of gastric carcinomas. Diagnostic value of the presence of signet-ring cells (SRC) in the endoscopic biopsy for the diagnosis of SRCC of the stomach, are unknown. Objectives To calculate the diagnostic values of the presence of SRC in endoscopic biopsy for the diagnosis of SRCC of the stomach in a definitive surgical specimen biopsy. Materials and Methods Retrospective diagnostic test study to determine the value of the presence of SRC in the endoscopic biopsy for the diagnosis of SRCC of the stomach in the surgical specimen biopsy. Inclusion criteria: Patients who underwent gastric surgery between 1996-2016. We calculated positive and negative predictive values (PPV and NPV), sensitivity, specificity, and positive and negative likelihood ratio (LR+ and LR−) of the presence of SRC in the endoscopic biopsy that predicts the diagnosis of SRCC of the stomach in the definitive biopsy. Confidence intervals (CI) of 95% were defined. Results The diagnostic values of the presence of SRC in endoscopic biopsy to diagnose SRCC of the stomach in the surgical specimen biopsy were: PPV of 56.1% (95% CI, 47.8-64.1%), NPV of 91.3% (95% CI, 89-93.1%), sensitivity of 55.7% (95% CI, 47.4-63.7%), specificity of 91.4% (95% CI, 89.1-93.3%), LR+ of 6.5 (95% CI, 4.9-8.6) and LR- of 0.48 (95% CI, 0.4-0.6), a positive post-test probability of 56.1% (95% CI, 47.8-64.1%), and a negative post-test probability of 8.7% (95% CI, 6.9-11%). Conclusions The presence of SRC in the endoscopic biopsy is not sufficient to diagnose SRCC of the stomach. The absence of SRC in the endoscopic biopsy has a high negative predictive value.

Related collections

Most cited references 27

Record: found
Abstract: not found
Article: not found

The Measurement of Observer Agreement for Categorical Data

J Landis, Gary G. Koch (1977)

0 comments Cited 6765 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Marc Ychou, Valérie Boige, Jean-Pierre Pignon … (2011)

After curative resection, the prognosis of gastroesophageal adenocarcinoma is poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma. Overall, 224 patients with resectable adenocarcinoma of the lower esophagus, gastroesophageal junction (GEJ), or stomach were randomly assigned to either perioperative chemotherapy and surgery (CS group; n = 113) or surgery alone (S group; n = 111). Chemotherapy consisted of two or three preoperative cycles of intravenous cisplatin (100 mg/m(2)) on day 1, and a continuous intravenous infusion of fluorouracil (800 mg/m(2)/d) for 5 consecutive days (days 1 to 5) every 28 days and three or four postoperative cycles of the same regimen. The primary end point was OS. Compared with the S group, the CS group had a better OS (5-year rate 38% v 24%; hazard ratio [HR] for death: 0.69; 95% CI, 0.50 to 0.95; P = .02); and a better disease-free survival (5-year rate: 34% v 19%; HR, 0.65; 95% CI, 0.48 to 0.89; P = .003). In the multivariable analysis, the favorable prognostic factors for survival were perioperative chemotherapy (P = .01) and stomach tumor localization (P < .01). Perioperative chemotherapy significantly improved the curative resection rate (84% v 73%; P = .04). Grade 3 to 4 toxicity occurred in 38% of CS patients (mainly neutropenia) but postoperative morbidity was similar in the two groups. In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.

0 comments Cited 589 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Advanced Gastric Carcinoma with Signet Ring Cell Histology

Chen Li, Sungsoo Kim, Ji Fu Lai … (2007)

Background: Gastric signet ring cell carcinoma (SRC) is a histological type based on microscopic characteristics and not on biological behavior. This study compared the clinicopathological features and prognosis of advanced SRC with non-signet ring cell adenocarcinoma (NSRC) of the stomach. Methods: We reviewed the records of 4,759 consecutive patients diagnosed with advanced gastric adenocarcinoma who were resected surgically from 1987 to 2003. Of these, 662 patients (13.9%) had SRC and were compared with 4,097 patients with NSRC. Results: Significant differences were noted in tumor size, Borrmann type, depth of invasion, lymph node metastasis, peritoneal dissemination and TNM stage. The cumulative 5-year survival rate for advanced SRC was 42.4%, compared with 50.1% in NSRC (p = 0.009). Multivariate analysis showed that tumor size ≧5 cm, Borrmann III and IV, T3–4 invasion and SRC histology were independent risk factors for lymph node metastasis. Depth of invasion, lymph node metastasis, hepatic and peritoneal metastasis and surgical curability were significant factors affecting survival. SRC histology alone was not an independent prognostic factor. Conclusions: Advanced gastric SRC tends toward deeper tumor invasion and more lymph node and peritoneal metastasis than NSRC. Advanced gastric SRC had a worse prognosis than NSRC. Therefore, curative surgical operation with extended lymph node dissection is recommended.